🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Eli Lilly patient assistance programs — looking for input Page 4

Eli Lilly patient assistance programs — looking for input

pam_stl Tue, Nov 11, 2025 at 2:34 PM 27 replies 1,587 viewsPage 4 of 6
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Nov 21, 2025 at 1:52 PM#16
traveltech_sara said:
pam_stl said: ...regarding the discontinuation data for cost and coverage...

Second this.

Last edited: Nov 21, 2025 at 4:52 PM
20 20sean_dublin, hannah_MT, Dr.SportsMedIN and 17 others
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Nov 23, 2025 at 2:31 AM#17
BethLabQueen said:
Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives: Prior authorization appeal…

No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.

Last edited: Nov 23, 2025 at 3:31 AM
19 19andrew_nyc, Dr.EndoEP, GraceAZ_72 and 16 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Nov 24, 2025 at 3:11 PM#18
BethLabQueen said:
Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives: Prior authorization appeal…

Saving this. It is the first explanation that did not require me to already understand it. Printing the relevant bit and taking it with me.

18 18SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 15 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Nov 26, 2025 at 3:52 AM#19

Adding the clinical framing, because it changes how the question reads. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

17 17SaraMom3, Dr.MetabolicMD, RetaRick_CA and 14 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Nov 27, 2025 at 4:34 PM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.

45 20PurityPaulOR, MaxMetOK, MounjBrad and 42 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register